Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
Rhea-AI Summary
Exousia Pro (OTCPK: MAJI) announced cancellation of derivative securities convertible into 47 million common shares via a mediation and exchange that replaced Series B preferred conversion rights with 2 million LMMY shares and a lock-up agreement. The company is progressing toward Definitive Agreements to acquire three telehealth targets, one of which scaled monthly revenue from $80,000 to $135,000 and will be the exclusive supplier to 1,900 clinics with an anticipated 2,000 prescriptions/day at $4.00 per script. Management targets a $200,000–$300,000 Regulation A raise to fund launches and plans a buyback once funding goals are met. A mediation is scheduled for March 13, 2026. The company has filed to rebrand as Nextel Medical Corp.
Positive
- 47 million potential common-share dilution cancelled
- Target telehealth revenue up $55,000 monthly (from $80k to $135k)
- Exclusive supplier agreement for 1,900 clinics with projected 2,000 scripts/day
- Reg A raise target of $200k–$300k to fund launches and testing
Negative
- Planned telehealth acquisitions are not closed; Definitive Agreements are pending
- Regulation A offering may cause dilution unless the proposed buyback is fully funded
- Mediation on March 13, 2026 leaves additional restricted-share outcomes unresolved
News Market Reaction – MAJI
In the Mar 5 session, MAJI gained 2.39%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint.
Major Capital Structure Optimization
Exousia Pro has successfully completed the cancellation of derivative securities convertible into 47 million shares of Common Stock. This substantial reduction was achieved through a strategic mediation and exchange agreement. In lieu of a prolonged legal dispute, the Company exchanged 2 million shares of LMMY for the cancellation of Series B Preferred shares (which were convertible into the 47 million common shares). As part of this transaction, Ludwig Enterprises, Inc. has entered into a formal lock-up and leak-out agreement regarding the LMMY shares, ensuring current and future market stability.
Telehealth Acquisition Momentum and Revenue Scaling
The Company is aggressively moving forward with Definitive Agreements to acquire three telehealth entities previously under Letter of Intent (LOI). Recent due diligence reveals exceptional growth:
- Revenue Growth: One target entity has scaled monthly revenue from
$80,000 t o$135,000 since December. - Strategic Partnership: Beginning in April, this entity will serve as the exclusive supplier for 1,900 clinics. With an anticipated volume of 2,000 prescriptions per day at a rate of
$4.00 per script, the Company anticipates a transformative impact on its consolidated revenue.
Commitment to Shareholder Value: Reg A & Buyback Program
Exousia Pro is currently utilizing a Regulation A offering to raise targeted capital for product launches and final testing. Management remains steadfast in its pledge to maintain a lean share structure. Upon reaching the funding goal of
Corporate Rebranding: Nextel Medical Corp.
Reflecting a new era of growth and a distinct market identity, the Company has filed for a name change with the State of Florida. The Company will transition from Exousia Pro, Inc. to Nextel Medical Corp. Shareholders may track the progress of this filing at www.sunbiz.org.
Litigation Update and Mediation
A mediation session is scheduled for Friday, March 13, 2026, at the request of the defendants. Management enters this session with a position of strength, seeking the full cancellation of additional restricted shares and further concessions to protect the float.
Executive Commentary
"This cancellation of 47 million shares is a landmark win for our shareholders, effectively removing a massive block of potential dilution and future distributions," said Matt Dwyer, President of Exousia Pro, Inc. "We are equally energized by the rapid scaling of our telehealth targets. The projected revenue from these acquisitions will provide a substantial boost to our balance sheet. Furthermore, our rebranding to Nextel Medical Corp. solidifies our unique identity in the biotech space. I look forward to providing live updates from our mediation on March 13th as we continue to advocate for the best interests of our investors."
About Exousia Pro, Inc. Exousia Pro, Inc. is a biotechnology company at the forefront of exosome research, focused on developing next-generation delivery systems for therapeutic and diagnostic applications. Through its expanding telehealth division, the Company aims to bridge the gap between clinical innovation and patient access.
Forward-Looking Statements: This press release contains forward-looking statements regarding the timing of definitive agreements and the expected benefits of acquisitions. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro
Investor Relations
ir@exousiapro.com
